Tokushima, Japan

Koichi Shinhama

USPTO Granted Patents = 17 


 

Average Co-Inventor Count = 7.7

ph-index = 5

Forward Citations = 119(Granted Patents)


Location History:

  • Osaka, JP (2013 - 2015)
  • Tokushima, JP (2009 - 2018)

Company Filing History:


Years Active: 2009-2018

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):

Title: The Innovative Mind of Koichi Shinhama: A Journey Through Patents and Contributions

Introduction: Koichi Shinhama, a prominent inventor based in Tokushima, Japan, has made significant strides in the field of pharmaceutical inventions. With a remarkable portfolio of 17 patents, his work primarily focuses on innovative drug formulations that improve medical treatments.

Latest Patents: Among his latest inventions is a patent for a low hygroscopic aripiprazole drug substance and the processes for its preparation. This invention presents low hygroscopic forms of aripiprazole which are crucial because they do not convert to a hydrate or lose their original solubility over extended storage periods. Such advancements ensure that medicinal preparations containing the anhydrous aripiprazole crystals remain effective and stable.

Career Highlights: Koichi Shinhama has had a commendable career working with notable companies such as Otsuka Pharmaceutical Company, Limited and Otsuka Pharmaceutical Co. Ltd. His expertise in drug development has not only advanced the pharmaceutical field but also significantly contributed to better patient outcomes.

Collaborations: Throughout his career, Shinhama has collaborated with esteemed professionals like Naoto Utsumi and Takuji Bando. These collaborations highlight the importance of teamwork in driving innovation and tackling complex challenges in the pharmaceutical industry.

Conclusion: Koichi Shinhama’s contributions to pharmaceutical inventions are noteworthy, reflecting his dedication to improving drug formulations. As an inventive mind focused on practical solutions, he continues to inspire future generations of inventors and researchers in the pharmaceutical domain.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…